Description: TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases. The company develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-380, a neutralizing HIV-1 antibody. The company was incorporated in 2007 and is headquartered in Taipei, Taiwan.
Home Page: www.taimedbiologics.com
No. 607, Ruiguang Road
Taipei,
11492
Taiwan
Phone:
886 2 2658 0058
Officers
| Name | Title |
|---|---|
| Mr. Chin-Ming Chang Ph.D. | Pres & CEO |
| Dr. David D. Ho M.D. | Scientific Co-Founder, Chief Scientific Advisor and Board Director |
| Dr. Ing-Wen Tsai Ph.D. | Co-Founder |
| Dr. Lan-Bo Chen Ph.D. | Co-Founder |
| Mr. Jack Chen | CFO & Chief of Corp. Governance |
| Hui Fang Zheng | Head of Audit Department |
Exchange: TWO
Country: TW : Taiwan
Currency: New Taiwan Dollar (NT$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 263.1579 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.4512 |
| Price-to-Sales TTM: | 55.9855 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |